In recent developments within the realm of neurology, Servier has made significant strides by introducing a promising drug for Fragile X Syndrome (FXS), a rare genetic disorder, through a licensing agreement with Kaerus Bioscience. This advancement comes on the heels of Harmony’s disappointing results with its synthetic cannabidiol gel, ZYN002, which failed to deliver expected outcomes in clinical trials for FXS.
Understanding Fragile X Syndrome
Fragile X syndrome is classified as a neuropsychiatric disorder and is recognized as a leading cause of inherited intellectual disability and autism spectrum disorder (ASD). While it affects individuals of all genders, males typically experience more severe symptoms than females. Currently, there are no FDA-approved therapies available for FXS, underscoring the urgent need for effective treatments.
Kaerus’ drug, KER-0193, is designed to rectify the abnormal functioning of BK channels, which contribute to neuronal hyperexcitability—a common symptom in FXS. This hyperexcitability manifests as hyperactivity, anxiety, sensory hypersensitivity, and seizures in patients. Established by Medicxi, a venture capital firm specializing in life sciences, KER-0193 represents a critical step toward addressing the complex needs of those affected by this disorder.
The Role of Neuroplasticity in Treatment
The third quarter of 2025 marked a notable period for FXS, with CONNECTA Therapeutics receiving EIC Accelerator funding to advance its neuroplasticity modulator, CTH120, into pediatric trials. Neuroplasticity, the brain’s ability to adapt and reorganize itself, is influenced by genetics, environmental factors, and pharmacological interventions. By targeting neuroplasticity, therapies can potentially restore cognitive and behavioral functions impaired in FXS and other central nervous system (CNS) disorders.
In a discussion with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Dr. Josep Prous Jr, co-founder and CSO, the complex nature of CNS disorders was highlighted. Fàbrega explained that these conditions often stem from widespread dysfunction across neural circuits, making targeted therapies challenging. The brain’s compensatory mechanisms can undermine the efficacy of treatments aimed at specific symptoms, illustrating the need for a more systemic approach.
The Promise of Restoring Neuroplasticity
Fàbrega emphasized that restoring neuroplasticity offers a more holistic solution than simply addressing individual symptoms. By doing so, it targets the root biological dysfunction underlying disorders like FXS. Traditional therapies often provide short-term relief but fail to rectify broader circuit-level issues.
CONNECTA’s lead compound, CTH120, aims to restore neuroplasticity balance by allosterically modulating TrkB, a critical regulator of neuroplasticity pathways. Preclinical studies have demonstrated its efficacy and safety, paving the way for Phase II clinical trials in adults with FXS to further explore its benefits.
Differentiating TrkB Modulation from Traditional Therapies
Dr. Prous outlined how CTH120’s mechanism differs from conventional treatments. While many strategies focus on correcting specific imbalances in neuronal signaling, TrkB modulation addresses the underlying connectivity of neurons. This broader approach allows for the restoration of normal neural functions, leading to improvements in cognition, behavior, and overall daily functioning.
Envisioning True Disease Modification
True disease modification for individuals with FXS entails more than symptom management. It encompasses significant improvements in cognitive abilities, behavioral health, and independence. Currently, most adults with FXS require support for daily activities; meaningful advancements could facilitate greater autonomy and participation in society.
Families and caregivers would also experience the benefits of disease modification, including reduced behavioral challenges and less emotional and financial strain. Ultimately, a hallmark of successful interventions will be the durability of improvements, indicating genuine restoration of neural functions rather than merely temporary relief.
Expanding Treatment Horizons with Small-Molecule Modulators
Small-molecule neuroplasticity modulators like CTH120 carry the potential to reshape treatment options across a spectrum of CNS conditions, including more prevalent disorders such as autism spectrum disorder and attention-deficit/hyperactivity disorder. Neuroplasticity imbalances are common to various conditions, making these modulators a compelling therapeutic target.
The advantages of small molecules include their ability to cross the blood-brain barrier, ease of oral administration, and adaptability in dosing regimens. This practical scalability ensures that treatments can be integrated into existing healthcare frameworks, facilitating broader access.
The Importance of Public-Private Partnerships
Public-private partnerships (PPPs) play a critical role in advancing therapies for rare neurodevelopmental disorders like FXS. By pooling resources and expertise from biotech companies, academic institutions, and patient advocacy groups, PPPs can streamline drug development processes. They enhance data quality and trial readiness, ultimately benefiting patients and families.
CONNECTA Therapeutics has actively engaged in PPPs to advance CTH120, fostering collaborations that align with patient needs while promoting efficient program development.
Addressing Challenges in Access and Adoption
As innovative therapies like CTH120 approach clinical application, several challenges must be navigated to ensure patient access. Demonstrating clear clinical benefits, particularly in terms of functional improvements, is vital for gaining support from families, regulators, and payers. Furthermore, clinician and caregiver awareness must be heightened to facilitate standardization of care and trial readiness.
Pricing and reimbursement issues also present hurdles, especially given the costs associated with rare disease treatments. Robust evidence of lasting benefits and health economics models that quantify the value of these therapies will be essential for widespread adoption.
In conclusion, the emergence of neuroplasticity modulators heralds a new era in the treatment of Fragile X Syndrome and other CNS disorders. By focusing on restoring neuroplasticity, these innovative therapies offer hope for meaningful improvements in the lives of patients and their families. With continued collaboration and commitment, the path forward is promising.
- Small-molecule neuroplasticity modulators may transform treatment options for rare and prevalent CNS conditions.
- Restoring neuroplasticity targets the underlying biological dysfunction rather than just managing symptoms.
- Public-private partnerships are crucial for optimizing drug development and patient-centric outcomes.
- Demonstrating clear clinical benefits will be essential for access and adoption of new therapies.
- True disease modification for FXS involves sustainable improvements in cognitive and behavioral health.
Read more → pharmaphorum.com